瑞舒伐他汀钙片联合厄贝沙坦片治疗老年原发性高血压肾病的临床研究
Clinical trial of rosuvastatin calcium tablets combined with irbesartan tablets in the treatment of elderly primary hypertension nephropathy
徐新伟 1赵军 1尹芳 1王佐良 1王健英1
作者信息
- 1. 潍坊市人民医院肾内科,山东 潍坊 261041
- 折叠
摘要
目的 观察瑞舒伐他汀钙片联合厄贝沙坦片治疗老年原发性高血压肾病的临床疗效和安全性.方法 将60例老年高血压肾病患者随机分为对照组30例和试验组30例.对照组予以厄贝沙坦片每次150 mg,qd,口服;试验组在对照组治疗的基础上,予以瑞舒伐他汀钙片每次10 mg,qd,口服.2组患者均治疗12周.比较2组患者的临床疗效、肝功能、肾功能,以及药物不良反应的发生情况.结果 治疗后,试验组和对照组的总有效率分别为93.33％(28例/30例)和90.00％(27例/30例),差异无统计学意义(P＞0.05).治疗后,试验组和对照组的总胆固醇含量分别为(3.92 ±0.67)和(5.54±1.33) mmol·L-1,三酰甘油分别为(1.61±0.45)和(2.16±0.84) mmol·L-1,低密度脂蛋白胆固醇分别为(2.25±0.62)和(2.76±0.84) mmol·L-1,血清肌酸酐分别为(75.70±14.87)和(78.16±18.84) μmol ·L-1,血尿素氮分别为(4.25±0.99)和(5.03±o.97)mmol· L-1,24h尿蛋白定量分别为(56.92±12.67)和(65.54±16.33)μg·24h-1,β2-微球蛋白分别为(353.65±27.43)和(389.16±27.84).μg·L-1,血清胱抑素C分别为(1.25 ±0.32)和(1.61 ±0.52) mg·L-1,超敏C-反应蛋白分别为(15.45 ±4.73)和(19.18±5.63) mmol·L-1,差异均有统计学意义(均P＜0.05).2组患者的药物不良反应以恶心、呕吐、头痛为主,试验组和对照组的总药物不良反应发生率分别为23.33％和20.00％,差异无统计学意义(P＞0.05).结论 瑞舒伐他汀钙片联合厄贝沙坦片治疗老年原发性高血压肾病的临床疗效和安全性与单用厄贝沙坦片相当,但前者可显著改善患者的肝、肾功能.
Abstract
Objective To observe the clinical efficacy and safety of rosuvastatin calcium tablets combined with irbesartan tablets in the treatment of elderly primary hypertension nephropathy.Methods A total of 60 elderly patients with primary hypertension nephropathy were randomly divided into control group and treatment group with 30 cases per group.Control group was given irbesartan tablets 150 mg per time,qd,orally.Treatment group received rosuvastatin calcium tablets l0 mg per time,qd,orally,on the basis of control group.The clinical efficacy,liver function,renal function and adverse drug reactions were compared between two groups.Results After treatment,the total effective rates in treatment and control groups were 93.33％ (28 cases/30 cases) and 90.00％ (27 cases/30 cases) without significant difference (P ＞0.05).After treatment,the main indexes in treatment and control groups were compared:the total cholesterol were (3.92 ± 0.67) and (5.54 ± 1.33)mmol · L-1,triglyceride were (1.61 ±0.45) and (2.16 ±0.84) mmol · L-1,low density lipoprotein cholesterol were (2.25 ± 0.62) and (2.76 ±0.84) mmol · L-1,serum creatinine were (75.70 ± 14.87) and (78.16 ± 18.84) μmol · L-1,blood urea nitrogen were (4.25 ± 0.99) and (5.03 ± 0.97) mmol · L-1,24 h urinary protein quantitation were (56.92±12.67) and (65.54 ± 16.33) μg · 24 h-1,β2-microspheres were (353.65 ± 27.43) and (389.16 ± 27.84) μg · L-1,serum cystatin C were (1.25 ± 0.32) and (1.61 ± 0.52) mg · L-1,high-sensitivity C-reactive protein were (15.45 ± 4.73) and (19.18 ± 5.63) mmol · L-1,the differences were significant (all P ＜ 0.05).The adverse drug reactions of two groups were based on nausea,vomiting and headache.The incidences of adverse drug reactions in treatment and control groups were 23.33％ and 20.00％ without significant difference (P ＞ 0.05).Conclusion Rosuvastatin calcium tablets combined with irbesartan tablets in the treatment of primary hypertension nephropathy in the elderly has the same clinical efficacy and safety as that of irbesartan tablet alone,but they can significantly improve the liver and kidney function of patients.
关键词
瑞舒伐他汀钙片/厄贝沙坦片/老年/原发性高血压肾病/安全性Key words
rosuvastatin calcium tablet/irbesartan tablet/elderly/primary hypertension nephropathy/safety引用本文复制引用
基金项目
山东省潍坊市卫生局科研基金资助项目(2011-02012)
出版年
2018
国家科技期刊平台
NSTL
维普
万方数据